Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked

NCT ID NCT07677852

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates sexual and urinary problems in people with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. While visible symptoms like droopy eyelids are well-known, issues like sexual dysfunction and bladder problems are often ignored. Researchers will use questionnaires to measure how common these hidden symptoms are and how they affect quality of life. The goal is to help doctors better recognize and address these underreported concerns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors recognize and address hidden symptoms like sexual and bladder issues in myasthenia gravis, potentially improving patients' quality of life.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change how the disease is managed. The results may not apply to all patients with myasthenia gravis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Myasthenic patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Minimum age of 18 years at the time the informed consent form is obtained. 2. Confirmed diagnosis of generalized autoimmune myasthenia gravis, including at least two of the following: 1. Typical clinical features assessed by a physician specializing in myasthenia gravis 2. A decrease of ≥ 10% during repeated nerve stimulation (3-5 Hz) or increased irregularity on a single-fiber electromyogram 3. A positive edrophonium test or response to anticholinesterase agents 4. Serum anti-AChR or anti-MuSK antibodies. 3. Enrolled in or covered by a social security program in accordance with current regulations governing research involving human subjects. Exclusion Criteria: 1. Pregnant (at the time of enrollment) 2. Postpartum \< 6 months 3. Severe cognitive impairment or under legal guardianship, making it impossible to understand or complete self-administered questionnaires.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis (MG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis (MG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP and Myology institute

    Paris, 75000, France

  • Nice University hospital

    Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.